References
- Becker-André M, André E, DeLamarter JF. Identification of nuclear receptor mRNAs by RT-PCR amplification of conserved zinc-finger motif sequences. Biochem Biophys Res Commun. 1993;194:1371–1379.
- Giguère V, Tini M, Flock G, et al. Isoform-specific amino-terminal domains dictate DNA-binding properties of ROR alpha, a novel family of orphan hormone nuclear receptors. Genes Dev. 1994;8:538–553.
- Carlberg C, Hooft Van Huijsduijnen R, Staple JK, et al. RZRs, a new family of retinoid-related orphan receptors that function as both monomers and homodimers. Mol Endocrinol. 1994;8:757–770.
- Hirose T, Smith RJ, Jetten AM. RORγ: the third member of ROR/RZR orphan receptor subfamily that is highly expressed in skeletal muscle. Biochem Biophys Res Commun. 1994;205:1976–1983.
- He Y-W, Deftos ML, Ojala EW, et al. RORγt, a novel isoform of an orphan receptor, negatively regulates Fas ligand expression and IL-2 production in T Cells. Immunity. 1998;9:797–806.
- McEwan IJ. Nuclear receptors: one big family. In: Walker JM, Ed. Methods in molecular biology: the nuclear receptor superfamily. Vol. 505. New York, (NY): Humana Press; 2009. p. 3‒18.
- Blumberg B, Evans RM. Orphan nuclear receptors – new ligands and new possibilities. Genes Dev. 1998;12:3149–3155.
- Zhang Y, Luo X-Y, D-h W, et al. ROR nuclear receptors: structures, related diseases, and drug discovery. Acta Pharmacol Sin. 2015;36:71–87.
- Fauber BP, Magnuson S. Modulators of the nuclear receptor retinoic acid receptor-related orphan receptor-γ (RORγ or RORc). J Med Chem. 2014;57:1299–1322.
- Yang J, Sundrud MS, Skepner J, et al. Targeting TH17 cells in autoimmune diseases trends. Pharmacol Sci. 2014;35:493–500.
- Isono F, Fujita-Sato S, Ito S. Inhibiting RORγt/TH17 axis for autoimmune disorders. Drug Discov Today. 2014;19:1205–1211.
- Rizvi S, Chaudhari K, Syed BA. The psoriasis drugs market. Nat Rev Drug Discov. 2015;14:745–746.
- FDA approves new psoriasis drug Cosentyx; [ cited 2016 June 29]. Available from: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm430969.htm
- FDA Approves New Psoriasis Drug Taltz; [ cited 2016 June 29]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm491872.htm
- Japan first to approve Lumicef worldwide; [ cited 2016 July 5]. Available from: https://drugnews.thomson-pharma.com/ddn/article.do?id=145459&from=alert#
- Anti-IL-17 therapy has shown signs of exacerbating Crohn’s disease. See: Fragoulis GE, Siebert S, McInnes IB. Therapeutic targeting of IL-17 and IL-23 cytokines in immune-mediated diseases. Ann Rev Med. 2016;67:337–353.
- Chang MR, He Y, Khan TM, et al. Antiobesity effect of a small molecule repressor of RORγ. Mol Pharmacol. 2015;88:48–56.
- Wang J, Zou JX, Xue X, et al. ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer. Nat Med. 2016;22:488–496.
- Hu X, Liu X, Moisan J, et al. RORγ agonists regulate immune checkpoint receptors to enhance anti-tumor immunity [Abstract Number 565]. In: Presented at AACR annual meeting. New Orleans (LA); 2016 April 17.
- Ueda E, Kurebayashi S, Sakaue M, et al. High incidence of T-cell lymphomas in mice deficient in the retinoid-related orphan receptor RORγ. Cancer Res. 2002;62:901–909.
- Jetten AM, Ueda E. Retinoid-related orphan receptors (RORs): roles in cell survival, differentiation and disease. Cell Death Differ. 2002;9:1167–1171.
- Ueda HR, Chen W, Adachi A, et al. A transcription factor response element for gene expression during circadian night. Nature. 2002;418:534–539.
- Jetten AM. Retinoid-related orphan receptors (RORs): critical roles in development, immunity, circadian rhythm, and cellular metabolism. Nucl Recept Signal. 2009;7:e003.
- Kurebayashi S, Ueda E, Sakaue M, et al. Retinoid-related orphan receptor γ (RORγ) is essential for lymphoid organogenesis and controls apoptosis during thymopoiesis. Proc Natl Acad Sci U S A. 2000;97:10132–10137.
- Sun Z, Unutmaz D, Zou Y-R, et al. Requirement for RORγ in thymocyte survival and lymphoid organ development. Science. 2000;288:2369–2373.
- Okada S, Markle JG, Deenick EK, et al. Impairment of immunity to candida and mycobacterium in humans with bi-allelic RORC mutations. Science. 2015;349:606–613.
- Vitae Pharmaceuticals press release: Vitae Pharmaceuticals Achieves Proof-of-Concept with First-in-Class RORγt Inhibitor in Mild to Severe Psoriasis; [ cited 2016 April 27] Available from: http://ir.vitaepharma.com/phoenix.zhtml?c=219654&p=irol-newsArticle&ID=2149044
- Thomson Reuters Cortellis: Search results for “retinoid Z receptor gamma”; [ cited 2016 May 2] Available from: https://cortellis.thomsonreuterslifesciences.com/ngg/#/qsearch/retinoid%20Z%20receptor%20gamma?indexBased=false&searchCategory=ALL
- Research Programme: Autoimmune Disorder Therapies – Arrien Pharmaceuticals – Adis Insight; [ cited 2016 April 1] Available from: http://adisinsight.springer.com/drugs/800044402
- Arrien Pharmaceuticals: News and Scientific Events; [ cited 2016 June 3] Available from: http://www.arrienpharma.com/news.php
- Arrien Pharmaceuticals Pipeline Overview; [ cited 2016 May 2] Available from: http://www.arrienpharma.com/arrienpipeline_overview.html
- Arrien Pharmaceuticals: Targeted Therapies: Inflammation/Autoimmune: Multiple Sclerosis (MS)/Psoriasis; [ cited 2016 May 10] Available from: http://www.arrienpharma.com/multiple_sclerosis.html
- Arrien Pharmaceuticals LLC. Substituted 2,3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis. WO2015038350, 2015.
- Study of Safety and Efficacy of Topical GSK2981278 – ClinicalTrials.gov; [ cited 2016 April 5] Available from: https://clinicaltrials.gov/ct2/show/NCT02548052
- Tempero, a wholly-owned subsidiary of GSK, also has an active RORγ program and has published several patent applications on phenyl acetamide RORγ inverse agonists, which will not be covered in this patent review.
- Smith SH, Peredo CE, Takeda Y, et al. Development of a topical treatment for psoriasis targeting RORγ: from bench to skin. PLoS One. 2016;11. DOI:10.1371/journal.pone.0147979.
- Drug Profile: GSK 2981278 – Adis Insight; [ cited 2016 May 21] Available from: http://adisinsight.springer.com/drugs/800043256
- Yang T, Liu Q, Cheng Y, et al. Discovery of tertiary amine and indole derivatives as potent RORγt inverse agonists. ACS Med Chem Lett. 2014;5:65–68.
- Wang Y, Cai W, Zhang G, et al. Discovery of N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides as potent RORγt inhibitors. Bioorg & Med Chem. 2014;22:692–702.
- Xiao S, Yosef N, Yang J, et al. Small-molecule RORγt antagonists inhibit T Helper 17 Cell transcriptional network by divergent mechanisms. Immunity. 2014;40:477–489.
- Wang Y, Cai W, Cheng Y, et al. Discovery of biaryl amides as potent, orally bioavailable, and CNS penetrant RORγt inhibitors. ACS Med Chem. 2015;6:787–792.
- Wang Y, Yang T, Liu Q, et al. Discovery of N-(4-aryl-5-aryloxy-thiazol-2-yl)-amides as potent RORγt inverse agonists. Bioorg & Med Chem. 2015;23:5293–5302.
- Glaxo Group Limited. Retinoid-related orphan receptor gamma modulators, composition containing them and uses thereof. WO2012100732, 2012.
- Glaxo Group Limited. Compounds useful as retinoid-related orphan receptor gamma modulators. WO2012100734, 2012.
- Glaxo Group Limited. Novel compounds. WO2012027965, 2012.
- Glaxo Group Limited. Novel compounds. WO2012028100, 2012.
- Glaxo Group Limited. Novel compounds. WO2013029338, 2013.
- Glaxo Group Limited. Sulfonamide compounds and their use in the modulation retinoid-related orphan receptor. WO2013045431, 2013.
- Glaxo Group Limited. Novel compounds. WO2013160418, 2013.
- Glaxo Group Limited. Novel compounds. WO2013160419, 2013.
- Glaxo Group Limited. Novel compounds. WO2015061515, 2015.
- Glaxo Group Limited. Modulators of the retinoid-related orphan receptor gamma (ROR-gamma) for use in the treatment of autoimmune and inflammatory diseases. WO2014086894, 2014.
- Glaxosmithkline (China) R&D Company Limited. Novel compounds. WO2015180612, 2015.
- Glaxosmithkline (China) R&D Company Limited. Novel compounds. WO2015180613, 2015.
- Glaxosmithkline (China) R&D Company Limited. Novel compounds. WO2015180614, 2015.
- Japan Tobacco Inc. Clinical development as of July 30, 2013. Available from: https://www.jt.com/investors/results/S_information/pharmaceuticals/pdf/P.L.20130730_E.pdf [ cited 2016 March 14].
- Research – Autoimmune Disease; [ cited 2016 April 27] Available from: http://www.orphagen.com/research_autoimmune.html
- Japan Tobacco Inc. Amide compound and pharmaceutical application therefor. WO2012147916, 2012
- 29 and 30 are drawn with the (R)- and (S)-stereochemistry, respectively, designated in the patent. Other reviews have drawn the epimer.
- Japan Tobacco Inc. Triazole-isoxazole compound and medical use thereof. WO2014065413, 2014.
- Hirata K, Kotoku M, Seki N, et al. SAR exploration guided by LE and FSP3: discovery of a selective and orally efficacious RORγ inhibitor. ACS Med Chem Lett. 2016;7:23–27.
- Japan Tobacco Inc. Clinical development as of May 2, 2016, [ cited Aug 25 2016]. Available from: https://www.jt.com/investors/results/S_information/pharmaceuticals/pdf/20160502_11.pdf
- Vitae Pharma – Pipeline; [ cited 2016 May 10] Available from: http://vitaepharma.com/pipeline/
- Vitae recently released plans to progress VTP-45489 into Phase 1 clinical trials in the third quarter of 2016. See: Adis Insight– VTP 45489; [ cited 2016 Aug 25]. Available from: http://adisinsight.springer.com/drugs/800047203
- Vitae press release – Vitae Pharmaceuticals Closes Public Offering of Common Stock; [ cited 2016 May 6] Available from: http://ir.vitaepharma.com/phoenix.zhtml?c=219654&p=irol-news&nyo=0
- Vitae Pharmaceuticals, INC. Thiazolopyrrolidine inhibitors of ROR-gamma. WO2014179564, 2014.
- Vitae Pharmaceuticals, INC. Dihydropyrrolopyridine inhibitors of ROR-gamma. WO2015116904, 2015.
- Gege C. Retinoid-related orphan receptor gamma t (RORγt) inhibitors from vitae pharmaceuticals (WO2015116904) and structure proposal for their Phase 1 candidate. Expert Opin Ther Pat. 2016;26:737–744.
- Vitae Pharmaceuticals, INC. Dihydropyrrolidine inhibitors of ROR-gamma. WO2016061160, 2016.
- Novartis press release– Novartis announces FDA approval for first IL-17A antagonist Cosentyx(™) (secukinumab) for moderate-to-severe plaque psoriasis patients; [ cited 2016 May 6] Available from: https://www.novartis.com/news/media-releases/novartis-announces-fda-approval-first-il-17a-antagonist-cosentyxtm-secukinumab
- Psoriasis treatments; [ cited 2016 May 21] Available from: https://www.psoriasis.org/about-psoriasis/treatments
- Innovimmune recent news – Innovimmune to present superior preclinical therapeutic efficacy results in rheumatoid arthritis of its INV-17 for ROR Gamma T inhibitor program at the 2014 American College of Rheumatology annual meeting; [ cited 2016 May 6] Available from: http://www.innovimmune.com/userfiles/INV_PR_14_002%20ACR%20for%20INV17%20RA%20Study(1).pdf
- Solt LA, Banerjee S, Campbell S, et al. ROR inverse agonist suppresses insulitis and prevents hyperglycemia in mouse model of type 1 diabetes. Endochrinology. 2015;156:869–881.
- Zürich ETH. ROR gamma modulators. WO2014147016, 2014
- Zürich ETH. ROR gamma modulators. WO2013041519, 2013
- Innovimmune recent news – ROR gamma inhibitor tested in lupus model; [ cited 2016 May 6]. Available from: http://www.innovimmune.com/userfiles/150611_INV-17%20Lupus%20Thursday_EULAR_2015.pdf
- NIH Small Business Innovation Research Grants – The development of RORgt immunomodulators targeting the TH17 axis in IBD – Visionary Pharmaceuticals; [ cited 2016 May 6] Available from: http://grantome.com/grant/NIH/R44-DK098896-02
- Very recently, Takeda announced the entry of their RORγt inverse agonist, TAK-828, into Phase 1 clinical trials for the treatment of Crohn’s disease. Takeda: R & D Pipeline. [cited 2016 Sep 19]. Available from: https://www.takeda.com/research/files/pipeline_20160729_en.pdf
- Scientific Approach – Immune Activation – RORγ agonists; [ cited 2016 May 6] Available from: http://www.lycera.com/scientific-approach/immune-activation/ror%CE%B3-agonists
- René O, Fauber BP, De Leon Boenig G, et al. Minor structural change to tertiary sulfonamide RORc ligands led to opposite mechanisms of action. ACS Med Chem Lett. 2015;6:798–803.